BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8878027)

  • 1. In situ distribution of integrin alpha 2 beta 1 and alpha-actinin in melanocytic proliferations.
    Duncan LM; Bouffard D; Howard C; Mihm MC; Byers HR
    Mod Pathol; 1996 Sep; 9(9):938-43. PubMed ID: 8878027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correspondence re: Duncan LM, Bouffard D, Howard C, Mihm MC Jr, Byers HR: In situ distribution of integrin alpha 2 beta 1 and alpha-actinin in melanocytic proliferation. Mod Pathol 9:938, 1996.
    Cramer SF
    Mod Pathol; 1996 Dec; 9(12):1178-9. PubMed ID: 8972479
    [No Abstract]   [Full Text] [Related]  

  • 3. Patterns of melastatin mRNA expression in melanocytic tumors.
    Deeds J; Cronin F; Duncan LM
    Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.
    Albelda SM; Mette SA; Elder DE; Stewart R; Damjanovich L; Herlyn M; Buck CA
    Cancer Res; 1990 Oct; 50(20):6757-64. PubMed ID: 2208139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
    Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
    Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.
    Natali PG; Hamby CV; Felding-Habermann B; Liang B; Nicotra MR; Di Filippo F; Giannarelli D; Temponi M; Ferrone S
    Cancer Res; 1997 Apr; 57(8):1554-60. PubMed ID: 9108459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
    Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
    Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of beta-1 integrins in organ specific adhesion of melanoma cells in vitro.
    Vink J; Thomas L; Etoh T; Bruijn JA; Mihm MC; Gattoni-Celli S; Byers HR
    Lab Invest; 1993 Feb; 68(2):192-203. PubMed ID: 7680081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of EphB6 expression in metastatic melanoma.
    Hafner C; Bataille F; Meyer S; Becker B; Roesch A; Landthaler M; Vogt T
    Int J Oncol; 2003 Dec; 23(6):1553-9. PubMed ID: 14612926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micro-anatomy related antigen expression in melanocytic lesions.
    Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
    J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours.
    Schadendorf D; Gawlik C; Haney U; Ostmeier H; Suter L; Czarnetzki BM
    J Pathol; 1993 Aug; 170(4):429-34. PubMed ID: 8105045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of galanin in melanocytic tumors].
    Gilaberte Y; Vera J; Coscojuela C; Roca MJ; Parrado C; González S
    Actas Dermosifiliogr; 2007; 98(1):24-34. PubMed ID: 17374330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
    Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
    Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adhesion molecule profile and malignancy of melanocytic lesions.
    Moretti S; Martini L; Berti E; Pinzi C; Giannotti B
    Melanoma Res; 1993 Aug; 3(4):235-9. PubMed ID: 8219755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
    Montone KT; van Belle P; Elenitsas R; Elder DE
    Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic beta-catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: potential implications for melanoma tumorigenesis?
    De Panfilis G; Ferrari D; Santoro S; Ricci R; Lombardi M; Pedrazzi G; Pepe C; Cortelazzi C; Santini M
    Br J Dermatol; 2009 Mar; 160(3):600-8. PubMed ID: 19183173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laminin-10 mediates basal and EGF-stimulated motility of human colon carcinoma cells via alpha(3)beta(1) and alpha(6)beta(4) integrins.
    Pouliot N; Nice EC; Burgess AW
    Exp Cell Res; 2001 May; 266(1):1-10. PubMed ID: 11339819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E-cadherin/catenin complex in benign and malignant melanocytic lesions.
    Silye R; Karayiannakis AJ; Syrigos KN; Poole S; van Noorden S; Batchelor W; Regele H; Sega W; Boesmueller H; Krausz T; Pignatelli M
    J Pathol; 1998 Dec; 186(4):350-5. PubMed ID: 10209482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
    Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
    Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.